Hennion & Walsh Asset Management Inc. Increases Holdings in MorphoSys AG (NASDAQ:MOR)

Hennion & Walsh Asset Management Inc. lifted its position in MorphoSys AG (NASDAQ:MOR) by 6.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 124,545 shares of the company’s stock after purchasing an additional 7,644 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.08% of MorphoSys worth $2,267,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of MorphoSys by 47.9% in the second quarter. GAMMA Investing LLC now owns 2,874 shares of the company’s stock worth $52,000 after acquiring an additional 931 shares during the last quarter. Carlson Capital L P acquired a new position in shares of MorphoSys during the 1st quarter worth about $17,241,000. Henry James International Management Inc. boosted its position in shares of MorphoSys by 105.8% during the 1st quarter. Henry James International Management Inc. now owns 88,506 shares of the company’s stock worth $1,605,000 after acquiring an additional 45,506 shares in the last quarter. SAL Trading LLC acquired a new stake in MorphoSys during the 1st quarter worth approximately $486,000. Finally, Susquehanna International Group Ltd. purchased a new position in shares of MorphoSys during the 1st quarter worth approximately $1,333,000. 18.38% of the stock is currently owned by hedge funds and other institutional investors.

MorphoSys Price Performance

NASDAQ MOR remained flat at $18.96 during mid-day trading on Monday. MorphoSys AG has a 52 week low of $4.18 and a 52 week high of $19.50. The company has a market capitalization of $2.86 billion, a PE ratio of -5.45 and a beta of 1.20. The stock has a 50 day moving average price of $18.51 and a 200-day moving average price of $18.06. The company has a debt-to-equity ratio of 4.98, a quick ratio of 1.38 and a current ratio of 1.38.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.